Overview
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2024-05-30
2024-05-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bristol-Myers Squibb
Criteria
Inclusion Criteria:- Diagnosis of plaque psoriasis (PsO) for ≥ 6 months
- Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs)
- Deemed by Investigator to be eligible for phototherapy or systemic therapy
- Psoriatic plaques must cover ≥ 10% of body surface area at baseline
- Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global
Assessment (sPGA) ≥ 3 at baseline
Exclusion Criteria:
- Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)
- Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions
that are commonly associated with PsO for which a participant requires current
systemic immunosuppressant medical treatment
- Any significant acute or chronic medical illness
Other protocol-defined inclusion/exclusion criteria apply